rolipram has been researched along with Autoimmune Diabetes in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rolipram was inhibitory at concentrations as low as 10(-8) to 10(-7) mol/l, and on a molar basis, it was 100-fold more effective than PTX." | 1.30 | The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. ( Beshay, E; Liang, L; Prud'homme, GJ, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, L | 1 |
| Beshay, E | 2 |
| Prud'homme, GJ | 2 |
| Croze, F | 1 |
2 other studies available for rolipram and Autoimmune Diabetes
| Article | Year |
|---|---|
The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antibodies, Monoclonal; CD3 Complex; Cyclic Nucleotide | 1998 |
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Autoimmune Diseases; Bucladesine; Cells, Cultured; | 2001 |